Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TYR | P14679 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423876 | 1.00 | KIF11 (0.70) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL1931781 | 0.97 | KIF11 (0.67) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL23319641 | 0.91 | KIF11 (0.61) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL4322427 | 0.91 | KIF11 (0.61) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL424728 | 0.89 | TSHR (0.73) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL3421942 | 0.88 | KIF11 (0.59) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL19192713 | 0.88 | TSHR (0.83) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL128222 | 0.88 | KIF11 (0.59) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL24599236 | 0.88 | TSHR (0.83) | KIF11TSHRLMNATYRNPC1 | |
| SCHEMBL2655921 | 0.86 | NPC1 (0.64) | KIF11TSHRLMNATYRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117396-A1 | AMMONIA PRODUCTION METHOD | UNIV NAT TAIWAN SCIENCE & TECHNOLOGY (TW) | 2026-04-30 | — | — | US | claimed |
| EP-4733441-A1 | AMMONIA PRODUCTION METHOD | National Taiwan University of Science and Technology (TW) | 2026-04-29 | — | — | EP | claimed |
| WO-2024263819-A2 | BORON-CONTAINING COMPOUNDS AND METHODS OF PREPARATION AND APPLICATIONS THEREOF | THE TRUSTEES OF BOSTON COLLEGE (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024224517-A1 | METHOD FOR PRODUCING SINGLE-CRYSTAL SPHERICAL SODIUM METAL NANOPARTICLES | エム・テクニック株式会社 | 2024-10-31 | — | — | WO | claimed |
| CN-117886790-A | Synthesis method of CochlearolB | 陕西师范大学 | 2024-04-16 | — | — | CN | claimed |
| WO-2024058239-A1 | HOLE TRANSPORTING MATERIAL FOR PHOTOELECTRIC CONVERSION ELEMENT FOR IMAGING ELEMENT OR ELECTRON BLOCKING MATERIAL FOR PHOTOELECTRIC CONVERSION ELEMENT FOR IMAGING ELEMENT, CONDENSED RING COMPOUND PRODUCTION METHOD, AND CONDENSED RING COMPOUND | 東ソー株式会社 | 2024-03-21 | — | — | WO | claimed |
| CN-116947925-A | Bridged biphenyl monophosphine ligand containing benzofuran structure, and preparation method and application thereof | 中山大学 | 2023-10-27 | — | — | CN | claimed |
| EP-3478669-B1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR | KEZAR LIFE SCIENCES (US) | 2023-08-30 | — | — | EP | claimed |
| CN-116135866-A | Bridged carboxylic acid-containing difunctional phosphine ligand, preparation method and application thereof | 中山大学 | 2023-05-19 | — | — | CN | claimed |
| EP-3068726-B1 | PREPARATION OF FUNCTIONALISED MATERIALS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2023-03-22 | — | — | EP | claimed |
| US-20080188671-A1 | Simple, inexpensive synthesis of high yield and purity Suzuki coupling compounds; inhibiting rearrangement | ARCHIMICA GMBH (DE) | 2008-08-07 | — | — | US | claimed |
| EP-1885729-A2 | METHOD FOR PRODUCING 2-FORMYLFURAN-4-BORONIC ACID BY THE METALATION OF 4-HALOFURFURAL ACETALS IN THE PRESENCE OF SUITABLE BORONIC ACID ESTERS OR ANHYDRIDES | Archimica GmbH (DE) | 2008-02-13 | — | — | EP | claimed |
| WO-2006122683-A2 | METHOD FOR PRODUCING 2-FORMYLFURAN-4-BORONIC ACID | ARCHIMICA GMBH (DE) | 2006-11-23 | — | — | WO | claimed |
| EP-1295887-B1 | Preparation of pure aryl lithium compounds | CHEMETALL GMBH (DE) | 2006-08-02 | — | — | EP | claimed |
| US-20050272963-A1 | Method for the production of acetylene alcohols | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-08 | — | — | US | claimed |
| EP-1295887-A1 | Preparation of pure aryl lithium compounds and their use | Chemetall GmbH (DE) | 2003-03-26 | — | — | EP | claimed |
| US-6503662-B1 | Tert-butylbenzene derivative prevents oxidation and decomposition of solvent at the time of charging which causes decreased battery characteristics | UBE INDUSTRIES, LTD. (JP) | 2003-01-07 | — | — | US | claimed |
| US-5929262-A | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-07-27 | — | — | US | claimed |
| EP-0817793-A2 | METHOD FOR PREPARING 17ALPHA-ACETOXY-11BETA-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES. | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1998-01-14 | — | — | EP | claimed |
| WO-1996030390-A2 | METHOD FOR PREPARING 17α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES. | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117396-A1 | AMMONIA PRODUCTION METHOD | HCN4, HCN2, HCN3 | KIF11 3895/4885TSHR 1899/4885LMNA 758/4885 |
| US-20080188671-A1 | Simple, inexpensive synthesis of high yield and purity Suzuki coupling compounds; inhibiting rearrangement | CBR3, CBR1, BLVRB | KIF11 959/4885TSHR 41/4885LMNA 3625/4885 |
| US-20050272963-A1 | Method for the production of acetylene alcohols | ADH1A, ADH1C, AKR1B10 | KIF11 1575/4885TSHR 295/4885LMNA 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.